(Total Views: 473)
Posted On: 03/11/2019 10:18:45 AM
Post# of 1460
Below is copied from IHUB,
Fletch
falconer66a Sunday, 03/10/19 10:05:39 PM
Re: nidan7500 post# 184573 0
Post # of 184635
The Anavex “Iceberg” An Entire Floating Glacier?
Yes, the ability of both of the lead Anavex sigma-1 receptor agonists, Anavex 2-73 (presently) and Anavex 3-71 (in later trials) to yield positive therapeutic outcomes for a wide diversity of diseases is high. Presently, the focus is only on the three central nervous system diseases being targeted in the human clinical trials being arranged and initiated: Rett syndrome, Parkinson’s disease, and Alzheimer’s. Any sort of therapeutic success with any one of that trio will make Anavex Life Sciences Corp a profit-making concern. But a very high probability that all three will yield favorable treatment results.
It is important to understand that so many other diseases and conditions share the root pathogenic dysfunctions addressed in the new paper; poorly-functioning autophagy, allowing toxic wastes to accumulate. The Anavex molecules restore functional sigma-1 receptor activities.
As I’ve conjectured before, I’m rather certain that Missling and the other Anavex principals know full well the potentials of their molecules. It was inadvertently from that understanding that Missling made the “tip of an iceberg” comment.
I’m eager to learn what a generalized dosing regimen of either of the molecules might do to prevent or suppress many (or most?) of the debilities that accompany otherwise normal aging. In that case, Anavex would be prescribed as a prophylactic, a generalized preventative; before any actual symptoms are presented. I’m hypothesizing that the Anavex molecules will have their best effects when administered before any symptoms appear; before cellular physiologies have been grossly disrupted (the full-symptom disease state).
Anavex therapies before symptoms present. With that, how many geriatric disease states could be stopped or delayed?
Part of that might well be by the very positive outcomes of enhanced sleep patterns and durations that the Anavex molecules appear to so safely induce.
Let’s watch all of this. A big but melting iceberg (good enough)? Or, a pair of molecules of glacial size aspects?
https://investorshub.advfn.com/boards/read_ms...=147429445
Fletch
falconer66a Sunday, 03/10/19 10:05:39 PM
Re: nidan7500 post# 184573 0
Post # of 184635
The Anavex “Iceberg” An Entire Floating Glacier?
Yes, the ability of both of the lead Anavex sigma-1 receptor agonists, Anavex 2-73 (presently) and Anavex 3-71 (in later trials) to yield positive therapeutic outcomes for a wide diversity of diseases is high. Presently, the focus is only on the three central nervous system diseases being targeted in the human clinical trials being arranged and initiated: Rett syndrome, Parkinson’s disease, and Alzheimer’s. Any sort of therapeutic success with any one of that trio will make Anavex Life Sciences Corp a profit-making concern. But a very high probability that all three will yield favorable treatment results.
It is important to understand that so many other diseases and conditions share the root pathogenic dysfunctions addressed in the new paper; poorly-functioning autophagy, allowing toxic wastes to accumulate. The Anavex molecules restore functional sigma-1 receptor activities.
As I’ve conjectured before, I’m rather certain that Missling and the other Anavex principals know full well the potentials of their molecules. It was inadvertently from that understanding that Missling made the “tip of an iceberg” comment.
I’m eager to learn what a generalized dosing regimen of either of the molecules might do to prevent or suppress many (or most?) of the debilities that accompany otherwise normal aging. In that case, Anavex would be prescribed as a prophylactic, a generalized preventative; before any actual symptoms are presented. I’m hypothesizing that the Anavex molecules will have their best effects when administered before any symptoms appear; before cellular physiologies have been grossly disrupted (the full-symptom disease state).
Anavex therapies before symptoms present. With that, how many geriatric disease states could be stopped or delayed?
Part of that might well be by the very positive outcomes of enhanced sleep patterns and durations that the Anavex molecules appear to so safely induce.
Let’s watch all of this. A big but melting iceberg (good enough)? Or, a pair of molecules of glacial size aspects?
https://investorshub.advfn.com/boards/read_ms...=147429445
(2)
(0)
